We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us

Download Mobile App





COVID-19 Antibodies Last Only Months, Calling for Stronger and Longer Lasting Vaccine Protection

By HospiMedica International staff writers
Posted on 16 Jul 2020
Print article
Illustration
Illustration
People infected with the novel coronavirus could see a decline in their natural immunity to the virus within months, which means that the vaccines currently being developed will have to generate stronger and longer lasting protection, or may have to be given at regular intervals.

A new pre-print paper released on the medical server medrxiv.org but not yet published in a peer-reviewed medical journal suggests that antibody responses could begin declining 20 to 30 days after COVID-19 symptoms begin appearing. The team of UK researchers who wrote the paper also found that the severity of COVID-19 symptoms determined the magnitude of the antibody response. The researchers arrived at their conclusion after examining samples collected from 65 patients with confirmed COVID-19 up to 94 days after they began showing symptoms and from 31 health care workers who took antibody tests every one to two weeks between March and June. "We show that IgM and IgA binding responses decline after 20-30 days," the researchers wrote in their paper. While the study is yet to be peer reviewed, the findings are significant for COVID-19 vaccines currently under development.

"This work confirms that protective antibody responses in those infected with SARS-COV2, the coronavirus that causes COVID-19, appear to wane rapidly. Whilst longer lasting in those with more severe disease, this is still only a matter of months," said Stephen Griffins, associate professor in the University of Leeds School of Medicine, who was not involved in the new study, in a written statement. "Similar short-lived responses are seen against other human coronaviruses that predominantly cause only mild illness, meaning that we can be re-infected as time goes by and outbreaks can adopt seasonality. With the more serious, sometimes fatal, outcomes of SARS-COV2, this is troubling indeed. Vaccines in development will either need to generate stronger and longer lasting protection compared to natural infection, or they may need to be given regularly."

"But this study does reinforce the message that we can't assume someone who has had COVID-19 can't get it again just because they initially became antibody positive," said Dr. Mala Maini, professor of viral immunology and consultant physician at the University College London, who was not involved in the new study, in a statement. "It also means a negative antibody test now can't exclude you having had COVID-19 a few months ago. And it suggests vaccines will need to be better at inducing high levels of longer lasting antibodies than the natural infection or that doses may need to be repeated to maintain immunity."



Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
X-Ray Detector
FDR-D-EVO III

Print article

Channels

Critical Care

view channel
Image: The permeable wearable electronics developed for long-term biosignal monitoring (Photo courtesy of CityUHK)

Super Permeable Wearable Electronics Enable Long-Term Biosignal Monitoring

Wearable electronics have become integral to enhancing health and fitness by offering continuous tracking of physiological signals over extended periods. This monitoring is crucial for understanding an... Read more

Surgical Techniques

view channel
Image: NTT and Olympus have begun the world\'s first joint demonstration experiment of a cloud endoscopy system (Photo courtesy of Olympus)

Cloud Endoscopy System Enables Real-Time Image Processing on the Cloud

Endoscopes, which are flexible tubes inserted into the body's natural openings for internal examination and biopsy collection, are becoming increasingly vital in medical diagnostics. Their minimal invasiveness... Read more

Patient Care

view channel
Image: The newly-launched solution can transform operating room scheduling and boost utilization rates (Photo courtesy of Fujitsu)

Surgical Capacity Optimization Solution Helps Hospitals Boost OR Utilization

An innovative solution has the capability to transform surgical capacity utilization by targeting the root cause of surgical block time inefficiencies. Fujitsu Limited’s (Tokyo, Japan) Surgical Capacity... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The PATHFAST hs-cTnI-II high-sensitivity troponin assay has been developed for the PATHFAST Biomarker Analyzer (Photo courtesy of Polymedco)

POC Myocardial Infarction Test Delivers Results in 17 Minutes

Chest pain is the second leading cause of emergency department (ED) visits by adults in the United States, generating over 7 million visits annually. In the event of a suspected heart attack, physicians... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.